Novo Nordisk A/S
NOVO-B.CO is undervalued
CPH · Healthcare
FAIR PRICE
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
$292.40
MARKET PRICE
$369.39
FAIR PRICE
$76.99
MARGIN
COMMUNITY BUY ZONE
UNLOCKS AT 10
Where does the market buy NOVO-B.CO?
No one has priced NOVO-B.CO yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.
COMMUNITY MEDIAN
▓▓▓▓▓
BUYERS AT TODAY'S PRICE
▓▓ %
0/10 INVESTORS · 10 MORE TO UNLOCK
METRICS
NOW AVAILABLE
Get notified when NOVO-B.CO's fair price changes
Push notifications when NOVO-B.CO's valuation shifts. Available on iOS and Android.
FPI RATING
Strong profitability and high-quality fundamentals across the board.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$295.51
Fair price × 0.80
DISTANCE
1.1%
Price to entry level
At the current price of $292.40, NOVO-B.CO trades 1.1% below the conservative entry level of $295.51. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate NOVO-B.CO's fair price
Novo Nordisk A/S's fair price of $369.39 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $292.40, NOVO-B.CO trades 26.3% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting NOVO-B.CO's risk profile.
RELATIVE · 30%
Comparing NOVO-B.CO's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for NOVO-B.CO, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate NOVO-B.CO's fair value with your own inputs.
NOVO-B.CO DCF Calculator
Pre-filled with NOVO-B.CO's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter NOVO-B.CO's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of NOVO-B.CO's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare NOVO-B.CO against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for NOVO-B.CO.
Explore on BuliosFAQ
What is the fair price of NOVO-B.CO?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Novo Nordisk A/S is $369.39. At the current market price of $292.40, NOVO-B.CO trades 26.3% below its calculated fair value.
Is NOVO-B.CO overvalued or undervalued?+
Novo Nordisk A/S is currently undervalued based on our valuation model. The stock trades at $292.40, which is 26.3% below the fair price of $369.39. The P/E ratio of 11.2x is a key metric in the valuation.
What is the margin of safety for NOVO-B.CO?+
With a 20% margin of safety applied to the fair price of $369.39, the conservative entry level for NOVO-B.CO is $295.51. At the current market price of $292.40, the stock trades 1.1% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is NOVO-B.CO's fair price updated?+
We update fair price calculations for NOVO-B.CO daily after market close. The current fair price of $369.39 incorporates the latest market data and sector multiples.
What factors affect NOVO-B.CO's fair price calculation?+
NOVO-B.CO's fair price of $369.39 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 11.2x, ROE of 59.1%, and dividend yield of 1.28%.
Is NOVO-B.CO a good buy right now?+
At $292.40, NOVO-B.CO trades 26.3% below our fair value estimate of $369.39. The stock is currently undervalued. ROE stands at 59.1% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does NOVO-B.CO pay dividends?+
NOVO-B.CO has a dividend yield of 1.28%.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.